We are monitoring the impact of COVID-19 on APAC Rubella Vaccine Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 6182
Share on
Share on

Asia Pacific Rubella Vaccine Market Research Report - Segmented By End User & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends, & Forecasts (2021 to 2026)

Pulished: April, 2021
ID: 6182
Pages: 145

Asia Pacific Rubella Vaccine Market Size & Growth (2021 to 2026):

As per the research report, the size of the Asia Pacific Rubella Vaccine (Human Diploid Cell) Market was valued at USD XX billion in 2021 and is expected to reach USD XX billion by 2026 at XX % CAGR during the forecast period 2021 to 2026.

The increased incidence of rubella infection and the increase in condition resulting in congenital disabilities known as congenital rubella syndrome are the major factors driving the market growth, estimated to further increase the APAC rubella vaccine market in the years to come.

The efforts of vaccine manufacturers to partner with organizations such as UNICEF, WHO, and the GAVI to improve the immunization programs of these organizations are driving the growth of the rubella vaccine market. These joint initiatives help reach large populations, especially in developing and underdeveloped countries of the APAC region. Government initiatives for successful vaccination programs to reduce child mortality and genetic deformity rates underscore the growing market for rubella vaccines. In addition, the governments of under-developed countries are working to eradicate bacterial diseases, which represent a heavy economic burden.

A high level of air pollution and hygiene awareness to prevent the spread of germs to a large population in developing and underdeveloped countries is a crucial factor in airborne viral diseases. For example, according to India's serum institute, around 40-45% of childbearing age women were susceptible to Rubella infection. In addition, it observed that over 2 lakh babies were born with congenital disabilities caused due to rubella infection during pregnancy in the Indian sub-continent.

Many local government authorities are focusing on increasing the production of MMR vaccines with lesser side effects and more efficacy. It is supported by government-aided funds for R&D activities for vaccines and improved healthcare education for the population.

However, some of the factors hampering the APAC rubella vaccine market's growth are vaccine-related reactions, especially allergies and the underperformance with high selectivity of human diploid cells during the manufacture of rubella vaccines.

This research report on the APAC Rubella Vaccine Market has been segmented and sub-segmented into the following categories:

By End User:

  • Pediatric Rubella Vaccine
  • Adult Rubella Vaccine
  • Traveler Rubella Vaccine

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia-Pacific region is emerging as a critical market for rubella vaccines and will continue to grow significantly in the years to come. The India rubella vaccine market will grow owing to raising awareness among low-income people about rubella infection and their complications. Coupled with a growing number of free government-run immunization programs will boost the market growth.

Ministry of Health and Family Welfare campaigns aim to immunize 41 million children in India. The first phase of the campaign ran successfully in 2017, completing the initiative across these five states, namely Karnataka, Lakshadweep, Tamil Nadu, Goa, and Puducherry. This campaign was conducted in schools, community centers, and other health facilities where more than 3.35 million children have been immunized, reaching over 97.5% of the target age group.

Many key market players and governmental and non-governmental agencies are funding the development of the MMR vaccines. The Chinese rubella vaccine market is implementing awareness programs and campaigns to prevent the spread of the disease. The local government has solid regulations and patient safety guidelines, aiming to eradicate the disease for long-term impact, and is expected to have better growth opportunities during the forecast period.

KEY MARKET PLAYERS

The Top Companies in the APAC Rubella Vaccine Market profiled in the report are Merck & Co., Inc., GlaxoSmithKline Plc, Chiron Corporation (Novartis), Sanofi-Aventis, Serum Institute of India, Astellas Pharma Inc., AstraZeneca Plc. (Medimmune, LLC.), CSL Limited, Pfizer Inc., and Berna Biotech (Crucell).,

1. Introduction                                                 

                1.1 Market Definition                                    

                1.2 Study Deliverables                                  

                1.3 Base Currency, Base Year and Forecast Periods    

                1.4 General Study Assumptions                                

2. Research Methodology                                                           

                2.1 Introduction                                               

                2.2 Research Phases                                      

                                2.2.1 Secondary Research                           

                                2.2.2 Primary Research                 

                                2.2.3 Econometric Modelling                      

                                2.2.4 Expert Validation                  

                2.3 Analysis Design                                         

                2.4 Study Timeline                                          

3. Overview                                                       

                3.1 Executive Summary                                

                3.2 Key Inferences                                         

                3.3 Epidemology                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                    

                4.1 Market Drivers                                          

                4.2 Market Restraints                                    

                4.3 Key Challenges                                         

                4.4 Current Opportunities in the Market                                              

5. Market Segmentation                                                              

                5.1 End User                                      

                                5.1.1 Introduction                           

                                5.1.2 Pediatric Rubella Vaccine                  

                                5.1.3 Adult Rubella Vaccine                         

                                5.1.4 Traveler Rubella Vaccine                   

                                5.1.5  Y-o-Y Growth Analysis, By End User                            

                                5.1.6  Market Attractiveness Analysis, By End User                          

                                5.1.7  Market Share Analysis, By End User                            

6. Geographical Analysis                                                              

                6.1 Introduction                                               

                                6.1.1 Regional Trends                    

                                6.1.2 Impact Analysis                     

                                6.1.3 Y-o-Y Growth Analysis                        

                                                6.1.3.1 By Geographical Area     

                                                6.1.3.2 By End User        

                                6.1.4  Market Attractiveness Analysis                     

                                                6.1.4.1 By Geographical Area     

                                                6.1.4.2 By End User        

                                6.1.5  Market Share Analysis                      

                                                6.1.5.1 By Geographical Area     

                                                6.1.5.2 By End User        

                6.2 China                                             

                6.3 India                                              

                6.4 Japan                                            

                6.5 South Korea                                               

                6.6 Australia                                      

7. Strategic Analysis                                                       

                7.1 PESTLE analysis                                         

                                7.1.1 Political                     

                                7.1.2 Economic                 

                                7.1.3 Social                         

                                7.1.4 Technological                         

                                7.1.5 Legal                          

                                7.1.6 Environmental                       

                7.2 Porter’s Five analysis                                              

                                7.2.1 Bargaining Power of Suppliers                        

                                7.2.2 Bargaining Power of Consumers                    

                                7.2.3 Threat of New Entrants                     

                                7.2.4 Threat of Substitute Products and Services                              

                                7.2.5 Competitive Rivalry within the Industry                     

8. Market Leaders' Analysis                                                        

                8.1 Merck & Co. Inc.                                       

                                8.1.1 Overview                 

                                8.1.2 Product Analysis                   

                                8.1.3 Financial analysis                  

                                8.1.4 Recent Developments                       

                                8.1.5 SWOT analysis                       

                                8.1.6 Analyst View                          

                8.2 GlaxoSmithKline Plc                                

                8.3 Chiron Corporation                                 

                8.4 Sanofi-Aventis                                          

                8.5 Serum Institute of India                                        

                8.6 Astellas Pharma Inc.                                               

                8.7 AstraZeneca Plc.                                       

                8.8 CSL Limited                                 

                8.9 Pfizer Inc.                                    

                8.10 Berna Biotech                                         

9. Competitive Landscape                                                           

                9.1 Market share analysis                                            

                9.2 Merger and Acquisition Analysis                                       

                9.3 Agreements, collaborations and Joint Ventures                                         

                9.4 New Product Launches                                         

10. Market Outlook and Investment Opportunities                                                         

Appendix                                                           

                a) List of Tables                                

                b) List of Figures                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of Region, by End user along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market

                                                                                                                          

  1. Asia Pacific Rubella Vaccine  Market By End User, From 2021 to 2026 ( USD Billion )
  2. Asia Pacific Pediatric Rubella Vaccine Market By Region, From 2021 to 2026 ( USD Billion )
  3. Asia Pacific Adult Rubella Vaccine  Market By Region, From 2021 to 2026 ( USD Billion )
  4. Asia Pacific Traveler Rubella Vaccine Market By Region, From 2021 to 2026 ( USD Billion )
  5. Japan Rubella Vaccine  Market By End User, From 2021 to 2026 ( USD Billion )
  6. China Rubella Vaccine  Market By End User, From 2021 to 2026 ( USD Billion )
  7. India Rubella Vaccine  Market By End User, From 2021 to 2026 ( USD Billion )
  8. Australia Rubella Vaccine  Market By End User, From 2021 to 2026 ( USD Billion )
  9. South Korea Rubella Vaccine  Market By End User, From 2021 to 2026 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample